ACE2 and COVID-19: Notably, we identified six clinically approved drugs in CMAP that are currently being investigated in clinical trials (www.clinicaltrials.gov) for COVID‐19 (chloroquine, thalidomide, methylprednisolone, losartan, lopinavir, and ritonavir), none of which was found to alter ACE2 expression significantly (P > 0.1, Table EV1F).